Imagen de Portada

Disparities in Prescription of Long‐Acting GLP‐1s

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Katherine Wasden, Nora Sheu, Pourya Medhati, Thomas C. Tsai, Dong Wook Kim, Ali Tavakkoli, Caroline M. Apovian, Eric G. Sheu
Formato:	Artículo Open Access
Publicado:	Wiley 2026
Materias:	Obesity
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Metabolic bariatric surgery is associated with reduced adverse hepatic and extrahepatic outcomes, and lower all‐cause mortality, in patients with steatotic liver disease
por: Weronika Stupalkowska, et al.
Publicado: (2025)

Effect of Caloric Restriction on Predicted Risk of Incident Cardiovascular Disease and Type 2 Diabetes in Young Adults: Findings From the CALERIE 2 Trial
por: Ryan Chang, et al.
Publicado: (2026)

One Year of Exercise After Weight Loss Increases Postprandial GLP ‐1 Secretion in Contrast to Usual Activity or GLP ‐1 Receptor Agonist Treatment
por: Joachim Holt, et al.
Publicado: (2025)

Less frequent dosing of GLP‐1 receptor agonists as a viable weight maintenance strategy
por: Calvin C. Wu, et al.
Publicado: (2025)

Psychosocial Outcomes in Telemedicine and Long‐Acting Incretin‐Specific Behavioral Intervention
por: Leslie J. Heinberg, et al.
Publicado: (2026)

The Silver Jubilee (2025) of Insulin Glargine: Introducing the Era of Long‐Acting Insulin Analogues for Diabetes Mellitus
por: Geremia B. Bolli, et al.
Publicado: (2026)

Effectiveness of Telemedicine Prescribing and a Long‐Acting Obesity Medication Behavioral Program: A 24‐Week Single‐Arm Study
por: Leslie J. Heinberg, et al.
Publicado: (2025)

Nutritional considerations with antiobesity medications
por: Jaime P. Almandoz, et al.
Publicado: (2024)

Response to the Letter to the Editor by Bett et al.
por: Jaime P. Almandoz, et al.
Publicado: (2024)

Response to the Letter to the Editor by Athinarayanan
por: Jaime P. Almandoz, et al.
Publicado: (2024)

Association of GLP ‐1 Receptor Agonists With Hepatic Decompensation in the All of Us Research Program
por: Inyoung Hwang, et al.
Publicado: (2026)

GLP‐1 receptor agonists and retained gastric content: Is it much ado about nothing?
por: Michael Camilleri
Publicado: (2025)

Balancing procedural safety and therapeutic continuity: GLP‐1 receptor agonists and upper endoscopy
por: Lien‐Chung Wei, et al.
Publicado: (2025)

Weight Loss With GLP ‐1 Agonists in Nondiabetic Adults: Systematic Review and Network Meta‐Analysis
por: Michael Lim, et al.
Publicado: (2026)

The release of GLP‐1 from gut L cells is inhibited by low extracellular pH
por: Philippa Garbutt, et al.
Publicado: (2024)

Safety and efficacy of glucagon‐like peptide‐1 (GLP‐1) receptor agonists in patients with weight regain or insufficient weight loss after metabolic bariatric surgery: A systematic review and meta‐analysis
por: Ali Esparham, et al.
Publicado: (2024)

Evaluating appetite/satiety hormones and eating behaviours as predictors of weight loss maintenance with GLP‐1RA therapy in adolescents with severe obesity
por: Megan O. Bensignor, et al.
Publicado: (2024)

The Impact of GLP ‐1‐Based Therapies on Cardiovascular Outcomes in Type 2 Diabetes: A Comprehensive Systematic Review and Network Meta‐Analysis
por: Shih‐Ming Chuang, et al.
Publicado: (2026)

GLP‐1 Receptor Agonists and Weight Loss: A Critical Review of Mechanisms
por: Giorgia Rutigliani, et al.
Publicado: (2026)

A GLP1R gene variant and sex influence the response to semaglutide treatment in patients with severe obesity
por: Aurélie Phan, et al.
Publicado: (2025)

GLP1Ra‐based therapies and DXA‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials
por: Kristen M. Beavers, et al.
Publicado: (2024)

Safety of GLP ‐1 and Dual GLP ‐1/ GIP Receptor Agonists in Preconception, Pregnancy, and Lactation: A Systematic Review of Maternal, Fetal, and Neonatal Outcomes
por: Lasin Ozbek, et al.
Publicado: (2026)

Sex differences in the efficacy of GLP ‐1 receptor agonists: A systematic review and meta‐analysis of cardiovascular and renal outcome trials
por: Hasan Fareed Siddiqui, et al.
Publicado: (2025)

Attitudes Toward Injectable GLP‐1 Drugs for Obesity Treatment: A Qualitative Interview Study With Healthcare Professionals
por: Raluca C. Capaian, et al.
Publicado: (2026)

Evaluating the Evolving Real‐World Adverse Events of GLP ‐ 1RAs Using FDA Adverse Event Reporting System ( FAERS )
por: David Stone, et al.
Publicado: (2026)

GLP‐1 Receptor Agonists and Substance Use Disorders in Older Adults With Type 2 Diabetes: A Target Trial Emulation
por: Hao Dai, et al.
Publicado: (2025)

Micronutrient and Nutritional Deficiencies Associated With GLP ‐1 Receptor Agonist Therapy: A Narrative Review
por: Jorge Urbina, et al.
Publicado: (2026)

Interpreting Pregnancy Risk After GLP ‐1 Receptor Agonists Discontinuation
por: Roberta Scairati, et al.
Publicado: (2026)

Efficacy and Safety of GLP ‐1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA
por: Binayak Sinha, et al.
Publicado: (2025)

Comparative Efficacy of Metabolic/Bariatric Surgery Versus GLP ‐1 Receptor Agonists: A Network Meta‐Analysis of Randomized Controlled Trials
por: Lucas Sabatella, et al.
Publicado: (2025)

Beyond GLP ‐1 Monotherapy: Novel Multi‐Agonists, Amylin Analogues, and Combination Strategies in Obesity and Type 2 Diabetes
por: Mikhail Khachaturov, et al.
Publicado: (2026)

Dietary Strategies and Nutritional Management in Patients Receiving GLP ‐1 and Dual GIP / GLP ‐1 Receptor Agonists as Adjuncts to Lifestyle Interventions: A Systematic Review of Randomised Clinical Trials
por: Rayanne Santos de Paulo, et al.
Publicado: (2026)

GLP‐1 therapy increases visceral adipose tissue metabolic activity: lessons from a randomized controlled trial in obstructive sleep apnea
por: Cliona O'Donnell, et al.
Publicado: (2024)

Acute GIP and GLP ‐1 Administration Exerts Differential Metabolic Effects in Totally Pancreatectomised Individuals
por: Liva S. L. Krogh, et al.
Publicado: (2026)

GLP ‐1 Receptor Agonists and Psychiatric Outcomes in Adolescents: A Systematic Review and Meta‐Analysis
por: Cynthia F. X. C. A. Silva, et al.
Publicado: (2026)

Residual Gastric Content in Hospitalised GLP ‐ 1RA Users: Considerations for Interpretation
por: Jiajia Xia
Publicado: (2026)

GLP ‐1 receptor agonists and cardiovascular events in metabolically healthy or unhealthy obesity
por: Tommaso Bucci, et al.
Publicado: (2025)

Interrupting prolonged sitting reduces postprandial GIP but not GLP ‐1 responses in type 2 diabetes
por: Beth K. Logan, et al.
Publicado: (2025)

Addressing the risk of ocular complications of GLP ‐ 1RAs ; a multi‐disciplinary expert consensus
por: Patrice Carter, et al.
Publicado: (2025)

Impact of GLP ‐1 Receptor Agonist Discontinuation on Liver‐Related Parameters: A Systematic Review and Meta‐Analysis
por: Matheus Souza, et al.
Publicado: (2026)